SDP2001

SDP2001 is a preclinical-stage therapeutic candidate being developed by Scindy Pharmaceutical for the treatment of drug-resistant bacterial infections. As an innovative antibacterial agent, it is designed to address the critical global health challenge of antimicrobial resistance (AMR). According to the company's pipeline, SDP2001 has progressed further into preclinical development compared to other early-stage discovery programs like SDP1001 and SDP1002. While the specific molecular target and chemical structure have not been publicly disclosed, the program reflects Scindy's focus on developing novel small molecule drugs to combat difficult-to-treat infections.